AZD8683 Single Ascending Dose Study
Study identifier:D1883C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled AZD8683 after Single Ascending Doses in Healthy Male Subjects
Medical condition
Healthy Volunteers
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD8683, Placebo
Sex
Male
Actual Enrollment
130
Study type
Interventional
Age
18 Years - 45 Years
Date
Study Start Date: 01 Oct 2009
Primary Completion Date: 01 Jan 2010
Study Completion Date: 01 Jan 2010
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: A AZD8683 | Drug: AZD8683 Solution for nebulisation, inhaled. Each subject will receive a single-dose of AZD8683 or placebo. Starting dose 1 ug (lung deposited dose) with up to 8 dose escalation not exceeding AstraZeneca pre-defined exposure limits. |
| Placebo Comparator: B Placebo | Drug: Placebo Solution for nebulisation, inhaled |
Contacts
Investigators
Principal Investigator
Gurdrun Schwabe
AstraZeneca R&D Lund
